Komori
Pharmarise Holdings (2796) · InitiativeRestated

Expanding Outside Directors and Establishing Nomination and Compensation Committees

First written in FY2016. 7 of 13 entries say "Restated". Latest entry: 2026-08-28.

13entries
11years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2018RestatedFY2021 – FY2022RestatedFY2024 – 2026-07-232016: 12017: 020172018: 120182019: 020192020: 120202021: 120212022: 120222023: 120232024: 220242025: 120252026: 42026
Same theme, other companies
Operation of the Nomination and Compensation Committee Centered on Independent Outside DirectorsA theme 192 companies write about · 0 as a headwind · 192 as a tailwind

The whole theme swung hardest in 2025: 9 of 89 companies on the "Worse" side.

87 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-28RestatedChanges in Directors and Officers

    「At the 40th annual general meeting of shareholders held today, the election of 9 directors and 1 audit & supervisory board member was approved. At the subsequent meeting of the Board of Directors, the Company determined the directors with titles and other matters, and hereby announces the details as follows.」

    The Company reaffirmed its governance structure through disclosure of its officer structure, including 3 outside directors and 2 outside audit & supervisory board members.
  2. FY2026RestatedAnnual report

    「The current number of outside directors is 3, and the current number of outside corporate auditors is 2.」

    We continue to maintain a governance framework comprising 3 outside directors, 2 outside corporate auditors, and the Nomination and Compensation Committee.
  3. FY2025RestatedAnnual report

    「The current number of outside directors is 3. The current number of outside corporate auditors is 2. In addition, a majority of the Board of Corporate Auditors consists of outside corporate auditors」

    We continue to maintain a framework comprising 3 outside directors, 2 outside corporate auditors, and a Board of Corporate Auditors with a majority of outside corporate auditors.
  4. FY2024Change in outside directors while maintaining 3 directorsAnnual report

    「Pursuant to a resolution at the Extraordinary General Meeting of Shareholders held on 29 January 2024, 1 outside director was additionally elected. Two directors retired upon expiration of their terms at the conclusion of the Annual General Meeting of Shareholders held on 29 August 2024, and 1 additional outside director was elected pursuant to a resolution at the same meeting, bringing the current number to 3.」

    Following the additional election of Aizawa Ai (相澤 愛), 2 directors retired, and Sonobe Tsuneo (園部経夫) was additionally elected. The outside-director structure now comprises 3 directors.
  5. FY2024-Q3AdvancedAnnual report

    「Director Aizawa Ai (相澤 愛) is an outside director and an independent officer designated under the rules of Tokyo Stock Exchange, Inc.」

    Aizawa Ai (相澤 愛) was newly appointed as an outside director effective 29 January 2024 and designated as an independent officer.
  6. FY2023SoftenedAnnual report

    「Pursuant to a resolution at the Annual General Meeting of Shareholders held on 28 August 2019, 2 additional outside directors were elected; 1 director resigned effective 31 May 2020; pursuant to a resolution at the Annual General Meeting of Shareholders held on 26 August 2020, 1 additional outside director was elected; and 2 directors resigned effective 23 May 2023, bringing the current number to 3.」

    The number of outside directors changed from the previous 5 to 3 following the resignation of 2 directors effective 23 May 2023. The Nomination and Compensation Committee continues to operate.
  7. FY2022RestatedAnnual report

    「Pursuant to a resolution at the Annual General Meeting of Shareholders held on 25 August 2016, 1 outside director was additionally elected. Pursuant to a resolution at the Annual General Meeting of Shareholders held on 28 August 2019, 2 additional outside directors were elected. One director retired upon resignation effective 31 May 2020, but 1 additional outside director was elected pursuant to a resolution at the Annual General Meeting of Shareholders held on 26 August 2020, bringing the current number to 5.」

    We continue to maintain a governance framework comprising 5 outside directors and the Nomination and Compensation Committee.
  8. FY2021RestatedAnnual report

    「Pursuant to a resolution at the Annual General Meeting of Shareholders held on 25 August 2016, 1 outside director was additionally elected. Pursuant to a resolution at the Annual General Meeting of Shareholders held on 28 August 2019, 2 additional outside directors were elected. One director retired upon resignation effective 31 May 2020, but 1 additional outside director was elected pursuant to a resolution at the Annual General Meeting of Shareholders held on 26 August 2020, bringing the current number to 5.」

    We continue to maintain a governance framework comprising 5 outside directors and the Nomination and Compensation Committee.
  9. FY2020AdvancedAnnual report

    「Pursuant to a resolution at the Annual General Meeting of Shareholders held on 25 August 2016, 1 outside director was additionally elected. Pursuant to a resolution at the Annual General Meeting of Shareholders held on 28 August 2019, 2 additional outside directors were elected. One director retired upon resignation effective 31 May 2020, but 1 additional outside director was elected pursuant to a resolution at the Annual General Meeting of Shareholders held on 26 August 2020, bringing the current number to 5.」

    Following the additional election and resignation of outside directors, the current number of outside directors is 5. The Nomination and Compensation Committee also continues to operate.
  10. FY2018RestatedAnnual report

    「Pursuant to a resolution at the 30th Annual General Meeting of Shareholders held on 25 August 2016, 1 additional outside director was elected, bringing the current number to 3.」

    We continue to maintain a framework comprising 3 outside directors and a Nomination and Compensation Committee with a majority of outside officers.
  11. FY2016First statedAnnual report

    「To further enhance corporate governance, 1 additional outside director was elected pursuant to a resolution at the 30th Annual General Meeting of Shareholders held on 25 August 2016, bringing the current total to 3.」

    The company has 3 outside directors and established a nomination and compensation committee with a majority of outside directors.
Moved together

"Expanding Scale and Store Network through M&A and New Store Openings" moved the same way as this thread, in the same document, in 3 of its 13 moves.

332222★123456
  1. ★This thread
  2. 1Expanding Scale and Store Network through M&A and New Store Openings3×
  3. 2Unprofitable Stores and the Risk of Impairment of Fixed Assets3×
  4. 3Strengthening Community Healthcare through Home Healthcare and Institutional Dispensing2×
  5. 4Profit improvement in the dispensing pharmacy business driven by an increase in prescriptions and fees for dispensing services2×
  6. 5Subsidiary Reorganization and More Efficient Store Operations2×
  7. 6Recruiting and Developing Pharmacists and Other Personnel2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview It last moved in the Changes in Directors and Officers of 2026-08-28: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expanding Outside Directors and Establishing Nomination and Compensation Committees | Pharmarise Holdings Corporation (2796) | Komori